Whilst IDO1 inhibitors can boost immunotherapy in mouse cancer models (88–91), the most advanced IDO1 inhibitor Epacadostat (INCB024360) could not potentiate anti-PD1 inhibitor pembrolizumab in a recent Phase III trial involving about 700 advanced melanoma patients (9, 92). This evidence concerns the gene IDO1 and cancer.